Kornimate/medical-research-clean huggingface dataset:
a comparison between gummetal and ss orthodontic wires in space closure

Conditions: Malocclusion, Angle Class I

Summary: when there is space present between our teeth orthodontically we have the ability to close them through many methods. using braces as our treatment modality this study will be investigating how efficient a new orthodontic wire is in closing tooth space. this new material is trade-named gummetal and claims to have many benefits to treating patients orthodontically. we will be exploring its efficiency in space closure compared to an industry standard (stainless steel). we predict that the stainless-steel orthodontic wire will be more efficient at space closure than the new gummetal wires.

this will be a randomized pilot split-mouth clinical trial of patients with spaces ≥ 3mm distal to the maxillary canines in need of closure through sliding mechanics. the sample consists of adolescent patients regardless of angle's molar malocclusion who are receiving comprehensive full fixed appliance orthodontic treatment. preformed conjoint archwires half being gummetal and the other half ss, will be utilized. each patient will have one side of the maxilla randomly allocated into the ss or gummetal treatment group. the study will follow a split-mouth design to reduce the confounding variables from patient to patient on space closure mechanics. the maxillary arch in each subject will be randomized into a ss side or gm side using a random number generator. spaces will be measured at; t0 is initial records, t1 is initiation of space closure, t2 will be 4 weeks after the initiation of space closure, t3 is another 4 weeks of space closure evaluation and t4 will be the final evaluation of space closure after 4 weeks from t3, via 3d intraoral scans of maxillary arches. space measurement and calculations will utilize 3shape software to measure the distance of canine movement based off the distal surface. sliding mechanics will be activated through niti coil springs from the maxillary canines to the maxillary molars. the force will be standardized to 150 gms and will be measured each visit. the same provider will activate the niti coil spring for retraction, along with data collection. superimposition of scans will be utilized to assess outcome measures.

Eligibility criteria:
inclusion criteria: * full permanent dentition (except third molars) * good general and oral health * bilateral spaces 3 \>/= mm distal to the maxillary canines * normal and hypodivergent growth pattern * any dental malocclusion * good oral hygiene exclusion criteria: * systemic diseases or syndrome * abnormalities in teeth size and/or shape * previous orthodontic treatment * anti-inflammatory medication * craniofacial anomalies * hyperdivergent growth pattern * periodontal disease / attachment loss exceeding 25% of root length * significant pre or in-treatment root resorption
indications for gallbladder surgery in gallstone disease

Conditions: Gallstones

Summary: the aim of the study is to identify patients with gallstone disease that should be operated and those that may potentially be observed. this selection was based on symptoms and clinical presentation. the consequences that may arise for the patient if observation is chosen compared with outcome after cholecystectomy has been markers of outcome.

1. randomized clinical trial (rct) of observation versus surgery for uncomplicated gallstone disease 2. rct of observation versus operation for acute cholecystitis 3. study of outcome after cholecystectomy in patients from 1. and 2. 4. study of symptoms in gallstone disease and symptom relief after cholecystectomy 5. long-term morbidity and mortality, including cancer, after cholecystectomy 6. long-term follow-up of patients with silent gallstones

Eligibility criteria:
inclusion criteria: * symptomatic gallstone disease (sgbs): episodes of pain in the right subcostal or midline epigastric area lasting more than 30 min, with ultrasonography signs of gallstones. * ultrasonographic: echo with an acoustic shadow in a visible gallbladder, or an echo with positional change and size \<3 mm or, alternatively no demonstrable gallbladder but a strong echo with an acoustic shadow in the position of the gallbladder exclusion criteria sgbs: * infrequent and/or minimal pain that need only very occasional medication * age below 18 or above 80 * not willing to participate inclusion criteria, acute cholecystitis (ac): * acute abdominal pain * duration of more than 8-12 h * tenderness on clinical examination in the upper right quadrant * presence of gallbladder stones and signs of inflammation on ultrasonography and in clinical biochemistry data, including an elevated temperature exclusion criteria, ac: * severe concomitant disease * suspected common bile duct stone * acalculous cholecystitis * localized peritonitis suggesting gallbladder perforation or gangrenous cholecystitis inclusion criteria 1983 cohort of patients: * participation in a screening study for gallstones in 1983 * operated for symptomatic gallstone disease in bergen, norway in 1983
prospectively collected pleural biopsies for validation of malignant pleural mesothelioma prognostic biomarkers

Conditions: Mesothelioma

Summary: this research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

the purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. currently, it is not possible to accurately determine cancer stage prior to surgery or another treatment. this new method may allow doctors to better classify cancer stage and give a better estimate for prognosis prior to surgery or another treatment. in this research study, the investigators would like to use biopsied tissue to study certain characteristics that will help test the new method for determining cancer stage and estimating prognosis. in this research study, the investigators are... * obtaining pleural specimens at the time of routine diagnostic biopsy during the participant's standard treatment. * storing your biopsied tissue * studying the tissue to determine if the new method of staging and prognosis is accurate and valid

Eligibility criteria:
inclusion criteria: * all adult patients with a diagnosis of malignant pleural mesothelioma undergoing * diagnostic pleural biopsy * pleuroscopy * and/or vats resections * participants must be 18 years of age or older. exclusion criteria: -any patient who is found to be unsuitable for * surgery, * treatment * diagnosis,

Keywords: mesothelioma
aging and cancer effects (ace) study

Conditions: Breast Cancer; Lung Cancer

Summary: hypotheses: 1. subjective self-reported data can be used to accurately reflect functioning across the 5 key domains. 2. cancer and its various treatment modalities will exert detrimental effects on the 5 key domains in older adults with cancer. 3. some aspect of baseline patient characteristic will be predictive of cancer-related outcomes.


Eligibility criteria:
inclusion criteria: * willing to do memory testing * willing to participate in activities of daily living assessment * can use a cane or walker * willing to complete a balance performance assessment, if able. exclusion criteria: * currently receiving treatment for cancer. * has a previous history of brain cancer * significant neurological disease other than ad that might affect cognitive function, such as stroke, parkinson's disease, multiple sclerosis, or serious traumatic brain injury.
french hypertrophic cardiomyopathy observatory

Conditions: Hypertrophic Cardiomyopathy

Summary: hypertrophic cardiomyopathy (hypertrophic cardiomyopathy=hcm) remains a poorly understood disease with an assumption insufficiently codified. there is no data available in france on the profile of patients, diagnostic methods and assessment and therapeutic use. the purpose of this study is to establish a monitoring of patients with hcm (sarcomere of origin or not) in france (diagnosis, treatment)

this both retrospective and prospective study is proposed to cardiology services 50 hospitals in france. a cardiologist referral is designated for each facility. the following data will be collected by the physician during the initial hospitalization * demographics * geographic origin of patient * clinical data: criteria for inclusion and non-inclusion data hcm general, doppler ultrasound, personal history, family history * reviews made: non-organic, biological * family survey, * treatments: medical, electrical, invasive * data from hospital the follow-up to 18 months, 3 years and 5 years will be conducted by clinical-research-technicians of the french society of cardiology, an application will be made to municipalities of birth and mail a letter to physicians and patients. the following data will be collected: * vital status * data from hospital * reviews made: non-organic, biological * treatments: medical, electrical, invasive

Eligibility criteria:
inclusion criteria: * age ≥ 15 years old * patient with hcm defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic exclusion criteria: * expressed refusal to participate in the study * significant aortic stenosis (\<1 cm ²)

Keywords: hypertrophic cardiomyopathy observatory lvh
remifentanil in extracorporeal shock wave lithotripsy

Conditions: Kidney Calculi

Summary: the purpose of this study is to compare the analgesic efficacy and side effects induced by administration of two different infusion rates of remifentanil, 0,05 mcg/ kg/ min versus 0,1mcg/ kg/ min, in order to determine which one is the most appropriate analgesic treatment to face extracorporeal shock wave lithotripsy.

remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases . this feature vouches for a predictable pharmacokinetics and makes this drug suitable for administration in continuous intravenous infusion in order to achieve patient conscious sedation during non-invasive surgical procedures. remifentanil could be particularly useful in day surgery setting, thanks also to its faster elimination than other oppioids. this property ensure a swift recovery from conscious sedation, reducing the period of time during which patient remains in recovery room and decreasing also the incidence of side effects, like ponv and respiratory depression. conscious sedation with remifentanil can provide patient comfort and cooperation during surgical procedure, since the verbal contact with the patient is kept up. extracorporeal shock wave lithotripsy (eswl) is a non-invasive procedure, contemplated as the first-line treatment for renal and upper ureteral stones, if stone diameter is ranged from 5 to 20 mm . it can grind calculi into fine particles, that are expelled through micturition. although many studies have been published in regard to continuous intravenous infusion of remifentanil, a small number of them focuses on which is the most appropriate infusion rate for eswl procedure.

Eligibility criteria:
inclusion criteria: * asa (american society of anaesthesiology) physical status between the i and class ii * body mass index (bmi) between 18 and 30. exclusion criteria: * patients who were unable to give informed consent or with diagnosis of depression * concurrent treatment with antidepressant * anxiolytic or with opioids or with history of abuse and dependence from these substances * allergy or intolerance to drugs administered in this study * severe cognitive deficits or psychiatric disorders * liver or renal impairment (aspartate aminotransferase \> 40 ui/l alanine aminotransferase \> 40 ui/l, creatinine \> 2mg/dl) * abnormal values of coagulation (international normalized ratio \> 1,2), platelet(\< 100.000/µl), arrhythmias and / or defect of atrioventricular conduction.

Keywords: remifentanil lithotripsy conscious sedation
validity and reliability of the turkish version of the post-liver transplant quality of life questionnaire

Conditions: Liver Transplant Disorder; Quality of Life

Summary: liver transplantation is a crucial treatment for life-threatening liver diseases, including acute liver failure, end-stage chronic liver disease, primary liver cancers, and congenital metabolic disorders. quality of life in liver transplant patients is vital. the world health organization defines quality of life as an individual's perception of their position in life within the context of culture, values, goals, and expectations. liver transplantation improves quality of life. recipients should be closely monitored and supported psychologically, with the effectiveness of the intervention in improving quality of life well-documented. saab et al. developed the post-liver transplantation quality of life (pltq) questionnaire, which includes eight sub-dimensions across 32 items. to our knowledge, no turkish-specific qol tool for liver transplant patients currently exists. this study aims to validate and assess the reliability of the turkish version of the pltq questionnaire.


Eligibility criteria:
inclusion criteria: * being 18 years of age or older, * having received post-liver transplant treatment at hacettepe university adult hospital general surgery units and being referred to hacettepe university, faculty of physical therapy and rehabilitation, cardiopulmonary rehabilitation unit after routine clinical and laboratory examinations, if deemed appropriate for the study, * being willing to participate in the study. exclusion criteria: * having undergone combined liver-kidney transplantation and multiple organ transplantation, * having uncontrolled cardiovascular and neurological problems, * having a cognitive problem that will prevent understanding the questionnaires, * not being willing to participate in the study.
factors affecting the effective end-tidal concentration of desflurane anaesthesia

Conditions: General Anesthetic Drug Adverse Reaction

Summary: there is accumulating evidence that inappropriate depth of anaesthesia is associated with increased risk of postoperative complications including risk of death. the aim of this study was to identify factors determining the effective end-tidal concentration (eetc) of desflurane, duration of wash in and wash out phase, and to estimate the risk of perioperative awareness in patients undergoing elective neurosurgical procedure.

all patients with american society of anesthesiologists (asa) physical status i-iii scheduled for elective neurosurgical procedure under general anaesthesia are studied. in each individual, the manufacturer recommended age-corrected end-tidal concentrations of desflurane is set and achieved initially. individual effective end-tidal concentration (eetc) of desflurane is then defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50. effective analgesia is maintained according to surgical plethysmographic index (spi) and dose of muscle relaxants according to neuromuscular transmission monitoring (tof). comorbidity, regular intake of alcohol and medication, smoking, sex, weight, height, and age are recorded. postoperative questionnaire is used to reveal the intraoperative awareness.

Eligibility criteria:
inclusion criteria: * asa i-iii * elective neurosurgical procedure under general anaesthesia * age between 18 and 78 * elective procedures with estimated duration 1 - 3 hours exclusion criteria: * glasgow coma scale gcs below 14 * other rhythm than sinus * pacemaker stimulation * planned postoperative ventilation

Keywords: desflurane end tidal concentration age anesthesia
sphenopalatine ganglion block for the treatment of post-stroke headache

Conditions: Headache; Stroke; Ischemic Stroke

Summary: determine the effects of sphenopalatine ganglion (spg) block in post-stroke headache.

the purpose of this study is to determine if sphenopalatine ganglion (spg) block is a safe and effective treatment for acute post-stroke headache. current literature lacks randomized controlled studies regarding the efficacy of different treatment modalities for acute post-stroke headache; additionally, there are no evidence-based guidelines for the treatment of acute post-stroke headache. sphenopalatine ganglion block is a non-invasive procedure where an anesthetic agent is injected into the nares, reaching the spg to relieve pain and autonomic features. this treatment has been effective in a variety of headache types but to our knowledge has not been studied in acute post-stroke headache.

Eligibility criteria:
inclusion criteria: 1. 18 years or older; 2. hospitalization at the university of utah hospital with a diagnosis of acute ischemic or hemorrhagic stroke; confirmed acute post-stroke headache by treating physician; 3. meets at least one of the following international classification of headache disorder-3 (ichd-3) criteria: 6.1.1.1 (acute headache attributed to ischemic stroke), 6.2.1 (headache attributed to non-traumatic intracerebral hemorrhage), 6.2.2 (acute headache attributed to non-traumatic subarachnoid hemorrhage); received at least one medication for headache during hospitalization. exclusion criteria: 1. previous treatment with spg block for post-stroke headache 2. history of prophylactic medication use for headache or migraine; 3. pregnant at time of stroke

Keywords: post-stroke headache sphenopalatine ganglion (spg) block
early use of ivabradine in heart failure

Conditions: Heart Failure With Reduced Ejection Fraction; Decompensated Heart Failure

Summary: the aim of the work is to evaluate the efficacy, quality of life and safety of early addition of ivabradine to b-blocker in reduced ef heart failure patients after acute decompensation compared to the standard treatment.

this study is a prospective randomized open label study will be conducted on egyptian patient with heart failure with reduced ejection fraction(ref hf). each of the eligible patients will be randomized to one of these groups, early administration of ivabradine and b-blocker group or control group which follows american heart association treatment guidelines of ref hf. the objectives include the following: 1. physical examination (heart rate, blood pressure, dyspnea and orthopnea symptoms) 2. nyha class 3. pro-nt-bnp serum level, st2 serum level 4. echocardiography (left ventricular ejection fraction) 5. score of minnesota living with heart failure questionnaire these objectives will be measured baseline, 2 weeks and after 3 months

Eligibility criteria:
inclusion criteria: 1. patient with acute heart failure either newly diagnosed or decompensated heart failure after stabilization 2. patients \> 18 years old 3. left ventricular ejection fraction less than 40 % of presumed irreversible etiology 4. clinically stable 24-48 hours after admission 5. sinus rhythm with heart rate above 70 bpm 6. no previous treatment with ivabradine exclusion criteria: 1. patients less than 18 years. 2. arterial fibrillation before inclusion. 3. ventricular dysfunction due to acute event (myocarditis, ami). 4- cardiogenic shock 5. patients are taking drug interact with ivabradine. 6- carrier or candidate for pacemaker, heart transportation, cardiac surgery or other cardiovascular procedure

Keywords: decompensated heart failure ivabradine st2 biomarker
effects of gum arabic ingestion on hormonal and metabolic changes in patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: to assess the effects on hormonal and metabolic changes in the pcos patients after ingestion of arabic gum

polycystic ovary syndrome (pcos) affects 5-20% of women of reproductive age worldwide it increases the risk for type 2 diabetes mellitus, cerebrovascular and cardiovascular events and not to mention it is one of the main causes of infertility. in the management of pcos life style modification like weight reduction is necessary and recently it was discovered that ga ingestion causes significant reduction in bmi and body fat percentage among healthy adult females.so if ga could also affect the hormones and the metabolic changes in pcos is going to be useful in decreasing the comorbidities and even treating pcos.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with pco by independent gynecologist exclusion criteria: * diabetic patients * menopausal women * history of allergy to gum arabic
minimally invasive decompression and fusion versus open for degenerative lumbar stenosis

Conditions: Lumbar Spinal Stenosis; Intervertebral Disc Degeneration

Summary: the purpose of this study is to determine the effectiveness of minimally invasive decompression and fusion over the traditional open decompression and fusion in patients with single-level lumbar stenosis caused by degenerative spondylolisthesis. postoperative follow-up will continue for 12 months. сlinical, safety, radiological and cost-effectiveness endpoints will be evaluated.


Eligibility criteria:
inclusion criteria: 1. age 40-75 years; 2. neurogenic claudication or bilateral radiculopathy caused by single level combination of degenerative stenosis and spondylolisthesis confirmed by mri at one level l3-l4 or l4-l5 or l5-s1; 3. symptoms persisting for at least three months prior to surgery; 4. given written informed consent form; 5. able and agree to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements; 6. oswestry disability index score of at least 40/100 at baseline; exclusion criteria: 1. bilateral foraminal stenosis requiring surgical decompression on both sides; 2. degenerative spondylolisthesis type 2b, 3 subtypes by gille; 3. more than one symptomatic level requiring multi-level surgical decompression and/or fusion; 4. any condition that cannot be treated with mini-invasive unilateral decompression and fusion; 5. any contraindication or inability to undergo baseline and/or follow up mri or x-ray as required per protocol; 6. spondylolisthesis grade ii or higher of any etiology; 7. prior lumbar spinal fusion at any level; 8. other non-degenerative spinal conditions that may have an impact on subject safety, wellbeing or the intent and conduct of the study; 9. history or presence of any other major neurological disease or condition that may interfere with the study assessments; 10. severe arterial insufficiency of the legs or other peripheral vascular disease; 11. previous enrollment in this study, current enrollment or plans to be enrolled in another study (in parallel to this study).